ArticleCore evidence2010
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis.
Article in Core evidence, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial.Bone marrow transplantation · 2014Trial
- Ayurvedic Drug Triphala in Combination with Providone Iodine Mitigates Radiation-Induced Mucositis in Head and Neck Cancer Patients without Affecting the Tumor Response.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023Article
- Therapeutic Intervention Using a Smad7-Based Tat Protein to Treat Radiation-Induced Oral Mucositis.International journal of radiation oncology, biology, physics · 2022Article
- Review
- Induced oral mucositis in Wistar rats treated with different drugs: Preventive potential in cytokine production.Molecular and clinical oncology · 2021Article
- The Japanese Herbal Medicine Hangeshashinto Induces Oral Keratinocyte Migration by Mediating the Expression of CXCL12 Through the Activation of Extracellular Signal-Regulated Kinase.Frontiers in pharmacology · 2021Article
- Mucoadhesive Electrospun Fibre-Based Technologies for Oral Medicine.Pharmaceutics · 2020Review
- The Japanese herbal medicine Hangeshashinto enhances oral keratinocyte migration to facilitate healing of chemotherapy-induced oral ulcerative mucositis.Scientific reports · 2020Article
- Cordycepin prevents radiation ulcer by inhibiting cell senescence via NRF2 and AMPK in rodents.Nature communications · 2019Article
- Heparin treatment mitigates radiation-induced oral mucositis in mice by interplaying with repopulation processes.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Article
- Bioactivity Determination of a Therapeutic Recombinant Human Keratinocyte Growth Factor by a Validated Cell-based Bioassay.Molecules (Basel, Switzerland) · 2019Article
- Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Inhibition of SIRT1 promotes taste bud stem cell survival and mitigates radiation-induced oral mucositis in mice.American journal of translational research · 2019Article
- Text mining-based in silico drug discovery in oral mucositis caused by high-dose cancer therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Povidone-iodine for the management of oral mucositis during cancer therapy.Oncology reviews · 2017Article
- Radiation-Induced Oral Mucositis.Frontiers in oncology · 2017Review
- Palifermin and Chlorhexidine Mouthwashes in Prevention of Chemotherapy-Induced Mucositis in Children with Acute Lymphocytic Leukemia: a Randomized Controlled Trial.Journal of dentistry (Shiraz, Iran) · 2016Article
- A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis.PloS one · 2016Article
- The role of Smad7 in oral mucositis.Protein & cell · 2015Review
- Review of preclinical studies on treatment of mucositis and associated pain.Journal of dental research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOral mucositis is a significant toxicity of cytotoxic chemo- and radiation-therapy used to treat cancer. Palifermin is the first pharmaceutical/biological agent approved for the intervention of oral mucositis. The major objective of this review is to evaluate the evidence supporting the use of palifermin.
methodsA literature search was performed using an appropriate keyword search in MEDLINE and PubMed databases.
resultsOf 100 full papers and 4 abstracts identified, 12 papers and 3 abstracts were appropriate for analysis. Level 2 evidence supporting palifermin use in patients with hematologic malignancies being treated with autologous hematopoietic stem cell transplantation (HSCT) is clear. Level 2 evidence also exists for the use of palifermin in the prevention of oral mucositis in patients with solid tumors (colorectal cancer, head and neck cancer), but is incomplete. Level >/= 3 data support the use of palifermin in allogeneic HSCT recipients and cycled chemotherapy. A single health economic study concluded that palifermin is essentially cost neutral in the autologous HSCT population.
conclusionData supporting the use of palifermin in autologous HSCT recipients with hematologic malignancies is clear. Some data exist demonstrating its efficacy in other oncologic indications. Additional studies are needed to broaden the potential applications of palifermin and to ascertain its economic, but not symptomatic, effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.